227 related articles for article (PubMed ID: 23921472)
41. Do risks of hormone therapy persist after discontinuation?
J Fam Pract; 2008 Jun; 57(6):366, 369. PubMed ID: 18677802
[No Abstract] [Full Text] [Related]
42. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial.
Jackson RD; Wactawski-Wende J; LaCroix AZ; Pettinger M; Yood RA; Watts NB; Robbins JA; Lewis CE; Beresford SA; Ko MG; Naughton MJ; Satterfield S; Bassford T;
J Bone Miner Res; 2006 Jun; 21(6):817-28. PubMed ID: 16753012
[TBL] [Abstract][Full Text] [Related]
43. From the Women's Health Initiative to the combination of estrogen and selective estrogen receptor modulators to avoid progestin addition.
Valera MC; Gourdy P; Trémollières F; Arnal JF
Maturitas; 2015 Nov; 82(3):274-7. PubMed ID: 26261036
[TBL] [Abstract][Full Text] [Related]
44. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study.
Crandall CJ; Hovey KM; Andrews CA; Chlebowski RT; Stefanick ML; Lane DS; Shifren J; Chen C; Kaunitz AM; Cauley JA; Manson JE
Menopause; 2018 Jan; 25(1):11-20. PubMed ID: 28816933
[TBL] [Abstract][Full Text] [Related]
45. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy.
Chlebowski RT; Anderson G; Pettinger M; Lane D; Langer RD; Gilligan MA; Walsh BW; Chen C; McTiernan A;
Arch Intern Med; 2008 Feb; 168(4):370-7; quiz 345. PubMed ID: 18299491
[TBL] [Abstract][Full Text] [Related]
46. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
Nozaki M; Koera K; Nagata H; Nakano H
J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
[TBL] [Abstract][Full Text] [Related]
47. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.
Chlebowski RT; Anderson GL; Sarto GE; Haque R; Runowicz CD; Aragaki AK; Thomson CA; Howard BV; Wactawski-Wende J; Chen C; Rohan TE; Simon MS; Reed SD; Manson JE
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26668177
[TBL] [Abstract][Full Text] [Related]
48. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo.
Murkes D; Lalitkumar PG; Leifland K; Lundström E; Söderqvist G
Gynecol Endocrinol; 2012 Oct; 28 Suppl 2():12-5. PubMed ID: 22834417
[TBL] [Abstract][Full Text] [Related]
49. Molecular Mechanism for Breast Cancer Incidence in the Women's Health Initiative.
Jordan VC
Cancer Prev Res (Phila); 2020 Oct; 13(10):807-816. PubMed ID: 32669317
[TBL] [Abstract][Full Text] [Related]
50. The SOGC statement on the WHI report on estrogen and progestin use in postmenopausal women.
Blake JM; Collins JA; Reid RL; Fedorkow DM; Lalonde AB; Christilaw J; Fortier M; Fortin C; Jolly EE; Lemay A; O'Grady T; Smith TE; Cooper J; Maxted JM; O'Grady K; Turek MA;
J Obstet Gynaecol Can; 2002 Oct; 24(10):783-90, 793-802. PubMed ID: 12399806
[TBL] [Abstract][Full Text] [Related]
51. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy.
Chlebowski RT; Anderson G; Manson JE; Pettinger M; Yasmeen S; Lane D; Langer RD; Hubbell FA; McTiernan A; Hendrix S; Schenken R; Stefanick ML
J Clin Oncol; 2010 Jun; 28(16):2690-7. PubMed ID: 20439627
[TBL] [Abstract][Full Text] [Related]
52. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
Prentice RL; Langer RD; Stefanick ML; Howard BV; Pettinger M; Anderson GL; Barad D; Curb JD; Kotchen J; Kuller L; Limacher M; Wactawski-Wende J;
Am J Epidemiol; 2006 Apr; 163(7):589-99. PubMed ID: 16484450
[TBL] [Abstract][Full Text] [Related]
53. The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice.
Lemay A
J Obstet Gynaecol Can; 2002 Sep; 24(9):711-5. PubMed ID: 12360366
[TBL] [Abstract][Full Text] [Related]
54. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
Shumaker SA; Legault C; Rapp SR; Thal L; Wallace RB; Ockene JK; Hendrix SL; Jones BN; Assaf AR; Jackson RD; Kotchen JM; Wassertheil-Smoller S; Wactawski-Wende J;
JAMA; 2003 May; 289(20):2651-62. PubMed ID: 12771112
[TBL] [Abstract][Full Text] [Related]
55. Perspectives on the Women's Health Initiative trial of hormone replacement therapy.
Grimes DA; Lobo RA
Obstet Gynecol; 2002 Dec; 100(6):1344-53. PubMed ID: 12468183
[TBL] [Abstract][Full Text] [Related]
56. Postmenopausal estrogen and progestin use in relation to breast cancer risk.
Newcomb PA; Titus-Ernstoff L; Egan KM; Trentham-Dietz A; Baron JA; Storer BE; Willett WC; Stampfer MJ
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):593-600. PubMed ID: 12101105
[TBL] [Abstract][Full Text] [Related]
57. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Parish SJ; Gillespie JA
Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
[TBL] [Abstract][Full Text] [Related]
58. The pharmacokinetics and efficacy of different estrogens are not equivalent.
Ansbacher R
Am J Obstet Gynecol; 2001 Feb; 184(3):255-63. PubMed ID: 11228470
[TBL] [Abstract][Full Text] [Related]
59. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer.
Colditz GA
J Natl Cancer Inst; 1998 Jun; 90(11):814-23. PubMed ID: 9625169
[TBL] [Abstract][Full Text] [Related]
60. Negative Women's Health Initiative findings stir consternation, debate among researchers.
Twombly R
J Natl Cancer Inst; 2006 Apr; 98(8):508-10. PubMed ID: 16622115
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
